Protocol Ledger

NCT06499688 · Phase III · COMPLETED

A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Interventional Phase III clinical trial protocol NCT06499688 sponsored by Chongqing Claruvis Pharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-28 Enrollment: 529 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06499688
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)529 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06499688
Protocol FieldVerified Registry Value
NCT IdentifierNCT06499688
Consolidated Lead SponsorChongqing Claruvis Pharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment529 participants (ACTUAL)
Registered Start Date2023-12-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI